Literature DB >> 28473441

Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study.

Julian C van Capelleveen1, Sophie J Bernelot Moens1, Xiaohong Yang1, John J P Kastelein1, Nicholas J Wareham1, Aeilko H Zwinderman1, Erik S G Stroes1, Joseph L Witztum1, G Kees Hovingh1, Kay-Tee Khaw1, S Matthijs Boekholdt1, Sotirios Tsimikas2.   

Abstract

OBJECTIVE: Apolipoprotein C-III (apoC-III) is a key regulator of triglyceride metabolism. Elevated triglyceride-rich lipoproteins and apoC-III levels are causally linked to coronary artery disease (CAD) risk. The mechanism(s) through which apoC-III increases CAD risk remains largely unknown. The aim was to confirm the association between apoC-III plasma levels and CAD risk and to explore which lipoprotein subfractions contribute to this relationship between apoC-III and CAD risk. APPROACH AND
RESULTS: Plasma apoC-III levels were measured in baseline samples from a nested case-control study in the European Prospective Investigation of Cancer (EPIC)-Norfolk study. The study comprised 2711 apparently healthy study participants, of whom 832 subsequently developed CAD. We studied the association of baseline apoC-III levels with incident CAD risk, lipoprotein subfractions measured by nuclear magnetic resonance spectroscopy and inflammatory biomarkers. ApoC-III levels were significantly associated with CAD risk (odds ratio, 1.91; 95% confidence interval, 1.48-2.48 for highest compared with lowest quintile), retaining significance after adjustment for traditional CAD risk factors (odds ratio, 1.47; 95% confidence interval, 1.11-1.94). ApoC-III levels were positively correlated with triglyceride levels, (r=0.39), particle numbers of very-low-density lipoprotein (r=0.25), intermediate-density lipoprotein (r=0.23), small dense low-density lipoprotein (r=0.26), and high-sensitivity C-reactive protein (r=0.15), whereas an inverse correlation was observed with large low-density lipoprotein particle number (r=-0.11), P<0.001 for each. Mediation analysis indicated that the association between apoC-III and CAD risk could be explained by triglyceride elevation (triglyceride, very-low-density lipoprotein, and intermediate-density lipoprotein particles), small low-density lipoprotein particle size, and high-sensitivity C-reactive protein.
CONCLUSIONS: ApoC-III levels are significantly associated with incident CAD risk. Elevated levels of remnant lipoproteins, small dense low-density lipoprotein, and low-grade inflammation may explain this association.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  C-reactive protein; apolipoprotein CIII; coronary artery disease; lipoproteins; triglycerides

Mesh:

Substances:

Year:  2017        PMID: 28473441      PMCID: PMC5484077          DOI: 10.1161/ATVBAHA.117.309007

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  27 in total

Review 1.  Mediation Analysis: A Practitioner's Guide.

Authors:  Tyler J VanderWeele
Journal:  Annu Rev Public Health       Date:  2015-11-30       Impact factor: 21.981

2.  Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics.

Authors:  Arman Qamar; Sumeet A Khetarpal; Amit V Khera; Atif Qasim; Daniel J Rader; Muredach P Reilly
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-06-11       Impact factor: 8.311

3.  Particle size distribution of lipoproteins from human atherosclerotic plaque: a preliminary report.

Authors:  J H Rapp; H W Harris; R L Hamilton; W C Krupski; L M Reilly; W K Ehrenfeld; R J Stoney; J Goldstone; J P Kane
Journal:  J Vasc Surg       Date:  1989-01       Impact factor: 4.268

4.  ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.

Authors:  Philip L S M Gordts; Ryan Nock; Ni-Huiping Son; Bastian Ramms; Irene Lew; Jon C Gonzales; Bryan E Thacker; Debapriya Basu; Richard G Lee; Adam E Mullick; Mark J Graham; Ira J Goldberg; Rosanne M Crooke; Joseph L Witztum; Jeffrey D Esko
Journal:  J Clin Invest       Date:  2016-07-11       Impact factor: 14.808

Review 5.  The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis.

Authors:  Moritz C Wyler von Ballmoos; Bernhard Haring; Frank M Sacks
Journal:  J Clin Lipidol       Date:  2015-05-14       Impact factor: 4.766

6.  Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation.

Authors:  Anette Varbo; Marianne Benn; Anne Tybjærg-Hansen; Børge G Nordestgaard
Journal:  Circulation       Date:  2013-08-07       Impact factor: 29.690

7.  Very-Low-Density Lipoprotein-Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III.

Authors:  Raimund Pechlaner; Sotirios Tsimikas; Xiaoke Yin; Peter Willeit; Ferheen Baig; Peter Santer; Friedrich Oberhollenzer; Georg Egger; Joseph L Witztum; Veronica J Alexander; Johann Willeit; Stefan Kiechl; Manuel Mayr
Journal:  J Am Coll Cardiol       Date:  2017-02-21       Impact factor: 24.094

Review 8.  Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.

Authors:  M John Chapman; Wilfried Le Goff; Maryse Guerin; Anatol Kontush
Journal:  Eur Heart J       Date:  2009-10-12       Impact factor: 29.983

9.  Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion.

Authors:  Chunyu Zheng; Veronica Azcutia; Elena Aikawa; Jose-Luiz Figueiredo; Kevin Croce; Hiroyuki Sonoki; Frank M Sacks; Francis W Luscinskas; Masanori Aikawa
Journal:  Eur Heart J       Date:  2012-08-26       Impact factor: 29.983

10.  Common variants associated with plasma triglycerides and risk for coronary artery disease.

Authors:  Ron Do; Cristen J Willer; Ellen M Schmidt; Sebanti Sengupta; Chi Gao; Gina M Peloso; Stefan Gustafsson; Stavroula Kanoni; Andrea Ganna; Jin Chen; Martin L Buchkovich; Samia Mora; Jacques S Beckmann; Jennifer L Bragg-Gresham; Hsing-Yi Chang; Ayşe Demirkan; Heleen M Den Hertog; Louise A Donnelly; Georg B Ehret; Tõnu Esko; Mary F Feitosa; Teresa Ferreira; Krista Fischer; Pierre Fontanillas; Ross M Fraser; Daniel F Freitag; Deepti Gurdasani; Kauko Heikkilä; Elina Hyppönen; Aaron Isaacs; Anne U Jackson; Asa Johansson; Toby Johnson; Marika Kaakinen; Johannes Kettunen; Marcus E Kleber; Xiaohui Li; Jian'an Luan; Leo-Pekka Lyytikäinen; Patrik K E Magnusson; Massimo Mangino; Evelin Mihailov; May E Montasser; Martina Müller-Nurasyid; Ilja M Nolte; Jeffrey R O'Connell; Cameron D Palmer; Markus Perola; Ann-Kristin Petersen; Serena Sanna; Richa Saxena; Susan K Service; Sonia Shah; Dmitry Shungin; Carlo Sidore; Ci Song; Rona J Strawbridge; Ida Surakka; Toshiko Tanaka; Tanya M Teslovich; Gudmar Thorleifsson; Evita G Van den Herik; Benjamin F Voight; Kelly A Volcik; Lindsay L Waite; Andrew Wong; Ying Wu; Weihua Zhang; Devin Absher; Gershim Asiki; Inês Barroso; Latonya F Been; Jennifer L Bolton; Lori L Bonnycastle; Paolo Brambilla; Mary S Burnett; Giancarlo Cesana; Maria Dimitriou; Alex S F Doney; Angela Döring; Paul Elliott; Stephen E Epstein; Gudmundur Ingi Eyjolfsson; Bruna Gigante; Mark O Goodarzi; Harald Grallert; Martha L Gravito; Christopher J Groves; Göran Hallmans; Anna-Liisa Hartikainen; Caroline Hayward; Dena Hernandez; Andrew A Hicks; Hilma Holm; Yi-Jen Hung; Thomas Illig; Michelle R Jones; Pontiano Kaleebu; John J P Kastelein; Kay-Tee Khaw; Eric Kim; Norman Klopp; Pirjo Komulainen; Meena Kumari; Claudia Langenberg; Terho Lehtimäki; Shih-Yi Lin; Jaana Lindström; Ruth J F Loos; François Mach; Wendy L McArdle; Christa Meisinger; Braxton D Mitchell; Gabrielle Müller; Ramaiah Nagaraja; Narisu Narisu; Tuomo V M Nieminen; Rebecca N Nsubuga; Isleifur Olafsson; Ken K Ong; Aarno Palotie; Theodore Papamarkou; Cristina Pomilla; Anneli Pouta; Daniel J Rader; Muredach P Reilly; Paul M Ridker; Fernando Rivadeneira; Igor Rudan; Aimo Ruokonen; Nilesh Samani; Hubert Scharnagl; Janet Seeley; Kaisa Silander; Alena Stančáková; Kathleen Stirrups; Amy J Swift; Laurence Tiret; Andre G Uitterlinden; L Joost van Pelt; Sailaja Vedantam; Nicholas Wainwright; Cisca Wijmenga; Sarah H Wild; Gonneke Willemsen; Tom Wilsgaard; James F Wilson; Elizabeth H Young; Jing Hua Zhao; Linda S Adair; Dominique Arveiler; Themistocles L Assimes; Stefania Bandinelli; Franklyn Bennett; Murielle Bochud; Bernhard O Boehm; Dorret I Boomsma; Ingrid B Borecki; Stefan R Bornstein; Pascal Bovet; Michel Burnier; Harry Campbell; Aravinda Chakravarti; John C Chambers; Yii-Der Ida Chen; Francis S Collins; Richard S Cooper; John Danesh; George Dedoussis; Ulf de Faire; Alan B Feranil; Jean Ferrières; Luigi Ferrucci; Nelson B Freimer; Christian Gieger; Leif C Groop; Vilmundur Gudnason; Ulf Gyllensten; Anders Hamsten; Tamara B Harris; Aroon Hingorani; Joel N Hirschhorn; Albert Hofman; G Kees Hovingh; Chao Agnes Hsiung; Steve E Humphries; Steven C Hunt; Kristian Hveem; Carlos Iribarren; Marjo-Riitta Järvelin; Antti Jula; Mika Kähönen; Jaakko Kaprio; Antero Kesäniemi; Mika Kivimaki; Jaspal S Kooner; Peter J Koudstaal; Ronald M Krauss; Diana Kuh; Johanna Kuusisto; Kirsten O Kyvik; Markku Laakso; Timo A Lakka; Lars Lind; Cecilia M Lindgren; Nicholas G Martin; Winfried März; Mark I McCarthy; Colin A McKenzie; Pierre Meneton; Andres Metspalu; Leena Moilanen; Andrew D Morris; Patricia B Munroe; Inger Njølstad; Nancy L Pedersen; Chris Power; Peter P Pramstaller; Jackie F Price; Bruce M Psaty; Thomas Quertermous; Rainer Rauramaa; Danish Saleheen; Veikko Salomaa; Dharambir K Sanghera; Jouko Saramies; Peter E H Schwarz; Wayne H-H Sheu; Alan R Shuldiner; Agneta Siegbahn; Tim D Spector; Kari Stefansson; David P Strachan; Bamidele O Tayo; Elena Tremoli; Jaakko Tuomilehto; Matti Uusitupa; Cornelia M van Duijn; Peter Vollenweider; Lars Wallentin; Nicholas J Wareham; John B Whitfield; Bruce H R Wolffenbuttel; David Altshuler; Jose M Ordovas; Eric Boerwinkle; Colin N A Palmer; Unnur Thorsteinsdottir; Daniel I Chasman; Jerome I Rotter; Paul W Franks; Samuli Ripatti; L Adrienne Cupples; Manjinder S Sandhu; Stephen S Rich; Michael Boehnke; Panos Deloukas; Karen L Mohlke; Erik Ingelsson; Goncalo R Abecasis; Mark J Daly; Benjamin M Neale; Sekar Kathiresan
Journal:  Nat Genet       Date:  2013-10-06       Impact factor: 38.330

View more
  22 in total

1.  Highlighting Residual Atherosclerotic Cardiovascular Disease Risk.

Authors:  Yunosuke Matsuura; Jenny E Kanter; Karin E Bornfeldt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-01       Impact factor: 8.311

2.  Evacetrapib and cardiovascular outcomes: reasons for lack of efficacy.

Authors:  Theodosios D Filippatos; Moses S Elisaf
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

3.  Increased atherosclerosis in a mouse model of glycogen storage disease type 1a.

Authors:  Anouk M La Rose; Anouk G Groenen; Benedek Halmos; Venetia Bazioti; Martijn G S Rutten; Kishore A Krishnamurthy; Mirjam H Koster; Niels J Kloosterhuis; Marieke Smit; Rick Havinga; Gilles Mithieux; Fabienne Rajas; Folkert Kuipers; Maaike H Oosterveer; Marit Westerterp
Journal:  Mol Genet Metab Rep       Date:  2022-04-21

4.  Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study.

Authors:  Julian C van Capelleveen; Sang-Rok Lee; Rutger Verbeek; John J P Kastelein; Nicholas J Wareham; Erik S G Stroes; G Kees Hovingh; Kay-Tee Khaw; S Matthijs Boekholdt; Joseph L Witztum; Sotirios Tsimikas
Journal:  J Clin Lipidol       Date:  2018-08-29       Impact factor: 4.766

5.  ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors.

Authors:  Natalie C Kegulian; Bastian Ramms; Steven Horton; Olgica Trenchevska; Dobrin Nedelkov; Mark J Graham; Richard G Lee; Jeffrey D Esko; Hussein N Yassine; Philip L S M Gordts
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-08-08       Impact factor: 10.514

6.  Apolipoprotein C-III predicts cardiovascular events and mortality in individuals with type 1 diabetes and albuminuria.

Authors:  Fanny Jansson Sigfrids; Lars Stechemesser; Emma H Dahlström; Carol M Forsblom; Valma Harjutsalo; Raimund Weitgasser; Marja-Riitta Taskinen; Per-Henrik Groop
Journal:  J Intern Med       Date:  2021-11-24       Impact factor: 13.068

7.  Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials.

Authors:  Amirhossein Sahebkar; Luis E Simental-Mendía; Niki Katsiki; Željko Reiner; Maciej Banach; Matteo Pirro; Stephen L Atkin
Journal:  BMJ Open       Date:  2019-02-22       Impact factor: 2.692

Review 8.  Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia.

Authors:  L Renee Ruhaak; Arnoud van der Laarse; Christa M Cobbaert
Journal:  Ann Clin Biochem       Date:  2019-03-19       Impact factor: 2.057

9.  Not Just Arterial Damage: Increased Incidence of Venous Thromboembolic Events in Cardiovascular Patients With Elevated Plasma Levels of Apolipoprotein CIII.

Authors:  Oliviero Olivieri; Gianni Turcato; Sara Moruzzi; Annalisa Castagna; Domenico Girelli; Francesca Pizzolo; Simonetta Friso; Marco Sandri; Antonella Bassi; Nicola Martinelli
Journal:  J Am Heart Assoc       Date:  2019-01-22       Impact factor: 5.501

10.  Elevated Lipoprotein(a) in Perinatally HIV-Infected Children Compared With Healthy Ethnicity-Matched Controls.

Authors:  Malon Van den Hof; Mirthe J Klein Haneveld; Charlotte Blokhuis; Henriette J Scherpbier; Hans P G Jansen; Neeltje A Kootstra; Geesje M Dallinga-Thie; Sander J H Van Deventer; Sotirios Tsimikas; Dasja Pajkrt
Journal:  Open Forum Infect Dis       Date:  2019-09-02       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.